Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $608.9 million.

  • Kymera Therapeutics' Cash from Financing Activities fell 84.25% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.3 million, marking a year-over-year decrease of 52.59%. This contributed to the annual value of $608.9 million for FY2024, which is 14424.12% up from last year.
  • Per Kymera Therapeutics' latest filing, its Cash from Financing Activities stood at $608.9 million for FY2024, which was up 14,424.12% from $4.2 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Cash from Financing Activities registered a high of $608.9 million during FY2024, and its lowest value of $4.2 million during FY2023.
  • In the last 3 years, Kymera Therapeutics' Cash from Financing Activities had a median value of $153.0 million in 2022 and averaged $255.3 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 97.26% in 2023, then soared by 14,424.12% in 2024.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Cash from Financing Activities stood at $289.3 million in 2020, then declined by 13.48% to $250.3 million in 2021, then plummeted by 38.87% to $153.0 million in 2022, then tumbled by 97.26% to $4.2 million in 2023, then surged by 14,424.12% to $608.9 million in 2024.